Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. A literature review

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 3, 2009, Pages 223-236

  Berardi, Rossana ^a   Verdecchia, Lorena ^a   Paolo, Marzia Di Pietro ^a   Giampieri, Riccardo ^a   Scartozzi, Mario ^a   Pierantoni, Chiara ^a   Bianconi, Maristella ^a   Mazzanti, Paola ^a   Cascinu, Stefano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Lung cancer; Molecular biology; NSCLC; Target therapies; Women

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AGATOLIMOD; BEVACIZUMAB; BORTEZOMIB; CANERTINIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FULVESTRANT; GEFITINIB; GEMCITABINE; LAPATINIB; LONAFARNIB; MARIMASTAT; MATUZUMAB; MOTESANIB; NAVELBINE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PICIBANIL; SORAFENIB; SUNITINIB; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONSTIPATION; DIET; ENVIRONMENTAL EXPOSURE; FEBRILE NEUTROPENIA; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; LUNG NEOPLASMS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RISK FACTORS; SMOKING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63749115762     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.06.008     Document Type: Review

References (119)

1. Williams M.D., and Sandler A.B. The epidemiology of lung cancer. Cancer Treat Res 105 (2001) 31-52
2. Levi F., Bosetti C., Fernandez E., et al. Trends in lung cancer among younf European women: the rising epidemic in France and Spain. Int J Cancer 121 2 (2007) 462-465
3. Coscio A.M., and Garst J. Lung cancer in women. Curr Oncol Rep 8 4 (2006) 248-251
4. Fu J.B., Kau T.Y., Severson R.K., and Kalemkerian G.P. Lung cancer in women: analysis of the national surveillance, epidemiology, and end results database. Chest 127 (2005) 768-777
5. Visbal A.L., Williams B.A., Nichols III F.C., et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 78 (2004) 209-215
6. Minami H., Yoshimura M., Miyamoto Y., Matsuoka H., and Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 118 (2000) 1603-1609
7. Kreuzer M., Boffetta P., Whitley E., et al. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer 82 1 (2000) 227-233
8. Zang E.A., and Wynder E.L. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88 (1996) 183-192
9. Mackay J., and Amos A. Women and tobacco. Respirology 8 2 (2003) 123-130
10. Henschke C.I., and Miettinen O. Women's susceptibility to tobacco carcinogens. Lung Cancer 43 (2004) 1-5
11. Wakelee H.A., Chang E.T., Gomez S.L., et al. Lung cancer incidence in never smokers. J Clin Oncol 25 (2007) 472-478
12. Subramanian J., and Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 25 (2007) 561-570
13. Boffetta P., Agudo A., Ahrens W., et al. Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. J Natl Cancer Inst 90 (1998) 1440-1450
14. Sobue T., et al. Japanese Public Health Center. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer 99 2 (2002) 245-251
15. Speizer F.E., Colditz G.A., Hunter D.J., Rosner B., and Hennekens C. Prospective study of smoking, antioxidant intake, and lung cancer in middle-aged women (USA). Cancer Causes Control 10 (1999) 475-482
16. Burns D.M. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer 89 (2000) 2506-2509
17. Canadian Cancer Registries Epidemiology Research Group. Lifetime residential and workplace exposure to environmental tobacco smoke and lung cancer in never-smoking women, Canada 1994-97. Int J Cancer 93 6 (2001 Sep) 902-906
18. Seow A., Wee-Teng P., Teh M., et al. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer epidemiology. Biomarkers Prevent 9 (2000) 1215-1221
19. Blackman J.A., Coogan P.F., Rosenberg L., et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11 7 (2002) 561-567
20. Behera D., and Balamugesh T. Indoor air pollution as a risk factor for lung cancer in women. J Assoc Phys India 53 (2005) 190-192
21. Brenner A.V., Wang Z., Kleinerman R.A., et al. Menstrual and reproductive factors and risk of lung cancer among Chinese women, Eastern Gansu Province, 1994-1998. J Epidemiol 13 1 (2003) 22-28
22. Khuder S.A. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 31 (2001) 139-148
23. Khuder S.A., and Mutgi A.B. Effect of smoking cessation on major histologic types of lung cancer. Chest 120 (2001) 1577-1583
24. Franceschi S., and Bidoli E. The epidemiology of lung cancer. Ann Oncol 10 l5 (1999) S3-S6
25. Zatloukal P., Kubik A., Pauk N., Tomasek L., and Petruzelka L. Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer 41 3 (2003) 283-293
26. Ebbert J.O., Yang P., Vachon, et al. Lung cancer risk reduction after smoking cessation: observations from a prospective Cohort of women. J Clin Oncol 21 5 (2003) 921-926
27. Wakelee H.A., Chang E.T., Gomez S.L., et al. Lung cancer incidence in never smokers. J Clin Oncol 25 5 (2007) 472-478
28. Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., and Calle E.E. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98 (2006) 691-699
29. Toyooka S., Tsuda T., and Gazdar A.F. The TP53 gene, tobacco exposure and lung cancer. Hum Mutat 21 (2003) 229-239
30. Wang T.J., and Zhou B.S. Meta-analysis of the potential relationship between exposure to environmental tobacco smoke and lung cancer in non-smoking Chinese women. Lung Cancer 16 2-3 (1997) 145-150
31. Enstrom J.E., and Kabat G.C. Environmental tobacco smoke and tobacco related mortality in a prospective study of Californians, 1960-1998. BMJ 326 (2003) 1057-1066
32. Stockwell H.G., Goldman A.L., Lyman G.H., et al. Environmental tobacco smoke and lung cancer risk in non-smoking women. J Natl Cancer Inst 84 18 (1992) 1417-1422
33. National Cancer Institute. Health effects of exposure to environmental tobacco smoke. The Report of the California Environmental Protection Agency. Smoking and Tobacco Control, Monograph no. 10, vol. 99. US Department of Health and Human Services, NIH, NCI; 1999. p. 4645.
34. De Andrade M., Ebbert J.O., Wampfler J.A., et al. Environmental tobacco smoke exposure in women with lung cancer. Lung Cancer 43 2 (2004) 127-134
35. Lubin J.H. Estimating lung cancer risk with exposure to environmental tobacco smoke. Environ Health Perspect 107 (1999) 879-883
36. Anderson K.E., Carmella S.G., Ye M., et al. Metabolites of a tobacco-specific lung carcinogen in non-smoking women exposed to environmental tobacco smoke. J Nat Cancer Inst 93 5 (2001) 378-381
37. Forastiere F., Mallone, Lo Presti E., et al. Characteristics of nonsmoking women exposed to spouses who smoke: epidemiologic study on environment and health in women from four italian areas environmental health perspectives 10 12 (2000) 1171-1177
38. Kubík A., Zatloukal P., Tomásek L., et al. Interactions between smoking and other exposures associated with lung cancer risk in women: diet and physical activity. Neoplasma 54 1 (2007) 83-88
39. Linseisen J., Rohrmann S., Miller A.B., et al. Fruit and vegetable consumption and lung cancer risk: updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 121 5 (2007) 1103-1114
40. Stabile L.P., Davis A.L., Gubish C.T., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
41. Mollerup S., Jorgensen K., Berge G., and Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37 (2002) 153-159
42. Oton A.B., Belani C., Cai C., et al. Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: an analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. J Clin Oncol 24 18S (2006) 7038
43. Belani C.P., von Pawel J., Pluzanska A., et al. Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advenced non-small cell lung cancer (NSCLC): analyses by gender. Lung Cancer 49 (2005) S235-S236 (P-452)
44. Wakalee H.A., Wang W., Schiller J.H., et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 1 (2006) 441-446
45. Singer J.W., Shaffer S., Baker B., et al. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 16 (2005) 243-254
46. Langer C.J., Socinski M.A., and O'Byrne K.J. Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): a phase III study. J Clin Oncol 23 Suppl. (2005) 623 (LBA7011)
47. Ross H., Bonomi P., Langer C., et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). J Clin Oncol 24 18S (2006) 7039
48. Wisnivesky J.P., and Halm E.A. Sex differences in lung cancer survival: do tumors behave differently in elderly women?. J Clin Oncol 25 (2007) 1705-1712
49. Ben-Zaken Cohen S., Pare P.D., Man S.F., and Sin D.D. COPD and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med 176 2 (2007) 113-120
50. Mollerup S., Ryberg D., Hewer A., Phillips D.H., and Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 59 (1999) 3317-3320
51. Thomsen J.S., Wang X., Hines R.N., and Safe S. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis 15 (1994) 933-937
52. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., and Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9 (2000) 3-28
53. Crofts F., Taioli E., Trachman J., et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15 (1994) 2961-2963
54. Mooney L.A., Bell D.A., Santella R.M., et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 18 (1997) 503-509
55. Nerurkar P.V., Okinaka L., Aoki C., et al. CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev 9 (2000) 1119-1122
56. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30 (1995) 445-600
57. Benhamou S., Lee W.J., Alexandrie A.K., et al. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 23 (2002) 1343-1350
58. Hung R.J., Boffetta P., Brockmoller J., et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 24 (2003) 875-882
59. Kure E.H., Ryberg D., Hewer A., et al. p53 mutations in lung tumors: relationship to gender and lung DNA adduct levels. Carcinogenesis 17 (1996) 2201-2205
60. Ng D.P.K., Tan Kar-Wai, Zhao B., and Seow A. CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes Control 16 (2005) 399-405
61. Bennett W.P., Alavanja M.C., Blomeke B., Vahakangas K.H., Castren K., and Welsh. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 91 23 (1999) 2009-2014
62. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
63. Douillard J.-Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage B-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
64. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus Cisplatin vs. observation in Resected Non-Small-Cell Lung Cancer. N Engl J Med 352 (2005) 2589-2597
65. Albain K.S., Unger J., Gotay C.C., et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials, Proc ASCO Part I. J Clin Oncol 25 (2007) 18S [abstr. 7549]
66. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
67. Zheng Z., Chen T., Li Z., Haura E., Sarma A., and et Bepler G. DNA synthesis and repair genes RRM1and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
68. Olaussen K., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
69. Ceppi P., Volante M., Novello S., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
70. Taioli E., and Wynder E.L. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86 (1994) 869-870
71. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
72. Schabath M.B., Wu X., Vassilopoulou-Sellin R., Vaporciyan A.A., and Spitz M.R. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10 (2004) 113-123
73. Patel J.D., Gray R.G., Stewart J.A., Skinner H.G., and Schiller J.H. Tamoxifen does not reduce the risk of lung cancer in women. J Clin Oncol 23 16S (2005) 7212
74. Traynor A.M., Schiller J.H., Stabile L.P., et al. Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC). J Clin Oncol 23 16S (2005) 7224
75. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
76. Lynch T.J., Adjei A.A., Bunn P.A., and DuBois R.N. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 10 (2004) 4199s-4204s
77. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
78. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
79. Herbst R.S., Giaccone G., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
80. Rivera M.P., and Stover D.E. Gender and lung cancer. Clin Chest Med 25 (2004) 391-440
81. West H.L., Franklin W.A., McCoy J., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24 (2006) 1807-1813
82. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
83. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
84. Kosaka T., Yatabe Y., Endoh H., et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8922
85. Huang S.F., Liu H.P., Li L.H., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
86. Marchetti A., Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
87. Toyooka S., Matsuo K., Shigematsu H., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 13 19 (2007) 5763-5768
88. Cappuzzo F., Magrini E., Ceresoli G.L., et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96 15 (2004) 1133-1141
89. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
90. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
91. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
92. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 11 (2005) 2445-2459
93. Hanna N., Lilenbaum R., Ansari R., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24 33 (2006) 5253-5258
94. Thienelt C., Bunn P., Hanna N., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 23 34 (2005) 8786-8793
95. Rosell R., Daniel C., Ramlau R., et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22 (2004) 620s [abstr. 7012]
96. Kelly K., Herbst R.S., Crowley J.J., et al. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): a randomized phase II selectional trial SWOG 0342. J Clin Oncol 24 (2006) 7015 [abstract]
97. Wood E.R., Truesdale A.T., McDonald O.B., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64 (2004) 6652-6659
98. http://www.cancer.gov/clinicaltrials
99. Folkman J. Tumor angiogenesis and tissue factors. Nat Med 2 (1996) 167-168
100. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
101. Fontanini G., Lucchi M., Vignati S., et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89 (1997) 881-886
102. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
103. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19 (2001) 851-856
104. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 11 (2004) 2184-2191
105. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
106. Brahmer J.R., Gray R., Schiller J.H., et al. ECOG 4599 phase III trial of carboplatin and paclitaxel ± bevacizumab: subset analysis of survival by gender. J Clin Oncol 24 Suppl. (2006) 373s [abstr 7036]
107. Heymach J.V., Johnson B.E., Prager D., et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. J Clin Oncol 24 Suppl. (2006) 368s [abstr 7016]
108. Hynes N.E., and Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta 1198 (1994) 165-184
109. Gusterson B.A., Gelber R.D., Goldhirsch A., et al. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10 (1992) 1049-1056
110. Kern J.A., Slebos R.J., Top B., et al. C-erbB2 expression and codon 12 k-ras both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93 (1994) 516-520
111. Tateishi M., Ispida T., Mitsudomi T., Kaneko S., and Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27 (1991) 1372-1375
112. Harpole Jr. D.H., Marks J.R., Richards W.G., Herndon J.E., and Sugarbaker D.J. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1 (1995) 659-664
113. Shi D., He G., Cao S., et al. Overexpression of the c-erbB-2/neu-encoded P185 protein in primary lung cancer. Mol Carcinog 5 (1992) 213-218
114. Scheurle D., Jahanzeb M., Aronsohn R.S., Watzek L., and Narayanan R. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved HercepTest. Anticancer Res 20 (2000) 2091-2096
115. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 (1996) 737-744
116. Krug L.M., Miller V.A., Patel J., et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 104 10 (2005) 2149-2155
117. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER-2 positive non-small-cell lung cancer. Ann Oncol 15 (2004) 19-27
118. Sakai K., Yokote H., Murakami-Murofushi K., Tamura T., Saijo N., and Nishio K. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 98 9 (2007) 1498-1503
119. Johnson B.E., and Janne P.A. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 12 14 (2006) 4436-4440